≥95% für empfindliche chromatographische und analytische Workflows, die minimale Basislinieninterferenzen erfordern.
Store at -20°C Versand Ice chest + Ice pads. Genaue Spezifikationen finden Sie im chargenspezifischen COA.
SDS, COA, Datenblatt und Spezifikationsblatt stehen zum Download bereit. Chargenspezifische COA über Chargennummernsuche abrufbar.
In 0 peer-reviewten Publikationen zu Chromatographie, organischer Synthese und Kreuzkupplungsreaktionen zitiert.
EHT 5372 is a highly potent and selective inhibitor of DYRK's family kinases with IC 50 s of 0.22, 0.28, 10.8, 93.2, 22.8, 88.8, 59.0, 7.44, and 221 nM for DYRK1A , DYRK1B , DYRK2 , DYRK3, CLK1, CLK2, CLK4, GSK-3α , and GSK-3β , respectively
In Vitro
EHT 5372 (0.1-10 μM; 24 hours) dose-dependently reduces pS396-Tau levels with an IC 50 of 1.7 μM whereas cell viability remains over 87% in all conditions. EHT 5372 (0.01-1 μM) inhibits the direct phosphorylation of Tau by DYRK1AEHT 5372 reduces Aβ production in a dose-dependent reduction with an IC 50 of 1.06 μM. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Viability AssayCell Line: HEK293 cells Concentration: 0.1, 0.5, 1, 5, 10 μM Incubation Time: 24 hours Result: Cell viability remained over 87% in all conditions. Western Blot AnalysisCell Line: HEK293 cells Concentration: 0.01, 0.03, 0.1, 0.3 , 1 μM Incubation Time: Result: Potently and dose-dependently inhibited Tau phosphorylation at pS396.
Form:Solid
IC50& Target:DYRK1A|0.22 nM (IC|50|)|DYRK1B|0.28 nM (IC|50|)|DYRK2|10.8 nM (IC|50|)|DYRK4|93.2 nM (IC|50|)|CLK1|22.8 nM (IC|50|)|CLK2|88.8 nM (IC|50|)|CLK4|59.0 nM (IC|50|)|GSK-3α|7.44 nM (IC|50|)|GSK-3β|221 nM (IC|50|)
Umfassendes Dokument zu Gefahren, Handhabung, Lagerung und Einhaltung regulatorischer Vorschriften.
<<<<<<< HEAD SDS herunterladen → ======= SDS herunterladen → >>>>>>> release248-p3Chargenspezifische Qualitätsdaten. Geben Sie Ihre Chargennummer ein, um das genaue COA abzurufen.
COA nachschlagen →Vollständige Qualitätsmerkmale und Akzeptanzkriterien für diese Qualität.
Spezifikationsblatt ansehen →Taxonomy Tree
| Kingdom | Organic compounds |
|---|---|
| Superclass | Organoheterocyclic compounds |
| Klasse | Diazanaphthalenes |
| Subclass | Benzodiazines |
| Intermediate Tree Nodes | Quinazolines |
| Direct Parent | Quinazolinamines |
| Alternative Parents | Benzothiazoles Dichlorobenzenes Aniline and substituted anilines Aminopyrimidines and derivatives Imidolactams Aryl chlorides Thiazoles Heteroaromatic compounds Carboximidic acids and derivatives Azacyclic compounds Organooxygen compounds Organochlorides Hydrocarbon derivatives Amines |
| Molecular Framework | Aromatic heteropolycyclic compounds |
| Substituents | Quinazolinamine - 1,3-benzothiazole - 1,3-dichlorobenzene - Aniline or substituted anilines - Aminopyrimidine - Chlorobenzene - Halobenzene - Aryl chloride - Aryl halide - Monocyclic benzene moiety - Pyrimidine - Imidolactam - Benzenoid - Heteroaromatic compound - Thiazole - Azole - Azacycle - Carboximidic acid derivative - Organochloride - Organohalogen compound - Hydrocarbon derivative - Organic oxygen compound - Organonitrogen compound - Organooxygen compound - Amine - Organic nitrogen compound - Aromatic heteropolycyclic compound |
| Beschreibung | This compound belongs to the class of organic compounds known as quinazolinamines. These are heterocyclic aromatic compounds containing a quianazoline moiety substituted by one or more amine groups. |
| External Descriptors | Not available |
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Löslichkeit | DMSO : 6.67 mg/mL (16.50 mM; ultrasonic and warming and heat to 60°C) |
|---|
